Stocks Health care ATYR
NASDAQ · Health careaTYR PHARMA INC (ATYR)
It posted a net loss of $60.8M. In fiscal 2025 capital spending exceeded operating cash flow by $62.1M. At June 30, 2026 it held $16.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about aTYR PHARMA INC
- Net worth
- aTYR PHARMA INC has a market value (market cap) of $741.5M at the latest share price, and shareholders' equity of $48.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $190K (-19.1% year on year), with a net loss of $74.1M.
- Cash flow
- In fiscal 2025 operations used $62M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- aTYR PHARMA INC's next report was expected around November 5, 2026 and is not on file with the SEC yet.
What aTYR PHARMA INC does
aTYR PHARMA INC is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ATYR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $190K | -$74.1M | -$0.80 | -$62.1M |
| 2024 | $235K | -$64M | -$0.86 | -$69.2M |
| 2023 | $353K | -$50.4M | -$0.94 | -$37.4M |
| 2022 | $10.4M | -$45.3M | -$1.60 | -$43.5M |
| 2021 | $0 | -$33.8M | -$1.77 | -$33.3M |
| 2020 | $10.5M | -$16.2M | -$1.77 | -$15.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ATYR ranks in Health care
Latest SEC filings
What aTYR PHARMA INC has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026Other event 8-K
- September 11, 2026Proxy statement DEF 14A
- August 31, 2026Preliminary proxy statement PRE 14A
- August 7, 2026
- August 7, 2026
- August 7, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 8, 2026
Insider trades
What the people running aTYR PHARMA INC did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Schimmel PaulDirector | Boughtindirect | 100,000 | $49.6K |
| February 4, 2026 | Denyes NancyGeneral Counsel | Sold | 1,118 | $1.1K |
| February 4, 2026 | Broadfoot Jill MarieChief Financial Officer | Sold | 1,558 | $1.5K |
| February 4, 2026 | Shukla SanjayPresident and CEO, Director | Sold | 3,745 | $3.7K |
| February 3, 2026 | Denyes NancyGeneral Counsel | Exercised options | 2,687 | - |
| February 3, 2026 | Broadfoot Jill MarieChief Financial Officer | Exercised options | 3,750 | - |
| February 3, 2026 | Shukla SanjayPresident and CEO, Director | Exercised options | 10,375 | - |
Who owns ATYR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 90 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Federated Hermes, Inc. | 8,509,678 | -2,000,000 |
| Vanguard Capital Management LLC | 3,808,091 | -4,041 |
| Kalehua Capital Management LLC | 3,576,334 | new |
| Aqr Capital Management LLC | 2,610,548 | +2,114,530 |
| Fmr LLC | 2,471,418 | -12,235,425 |
| BlackRock, Inc. | 1,827,332 | -4,616,572 |
| Jane Street Group, LLC | 1,721,297 | +1,672,795 |
| UBS Group AG | 1,531,151 | -2,336,062 |
| Morgan Stanley | 1,343,636 | +118,169 |
| Two Sigma Investments, LP | 1,245,147 | +100,582 |
| Citadel Advisors LLC | 1,242,067 | +1,194,695 |
| Geode Capital Management, LLC | 1,177,020 | -1,208,465 |
| Susquehanna International Group, Llp | 747,039 | -119,705 |
| Millennium Management LLC | 656,051 | -985,195 |
| Goldman Sachs Group Inc | 641,208 | +357,972 |
| Vanguard Fiduciary Trust Co | 576,125 | -75,707 |
| State Street Corp | 494,951 | -1,259,448 |
| Marshall Wace, Llp | 368,120 | +230,002 |
| XTX Topco Ltd | 226,678 | +115,255 |
| Northern Trust Corp | 220,141 | -490,964 |
Insiders
4 insiders reported holding 1,003,116 shares in total, about $7.6M at the last price.
| Holder | Shares |
|---|---|
| Schimmel PaulDirector | 779,143779,143 held indirectly |
| Shukla SanjayPresident and CEO, Director | 153,553 |
| Broadfoot Jill MarieChief Financial Officer | 37,296 |
| Denyes NancyGeneral Counsel | 33,124 |
Questions about ATYR
What does aTYR PHARMA INC do?
aTYR PHARMA INC is a company in the Health care sector, listed on NASDAQ as ATYR. Its shares trade on NASDAQ under the ticker ATYR.
What is aTYR PHARMA INC's net worth?
aTYR PHARMA INC has a market value (market cap) of $741.5M at the latest share price, and shareholders' equity of $48.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is aTYR PHARMA INC profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $60.8M.
When did aTYR PHARMA INC last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 1, 2026.
When is aTYR PHARMA INC's next earnings report?
aTYR PHARMA INC's next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare ATYR with
Follow ATYR
Get an email when aTYR PHARMA INC files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values aTYR PHARMA INC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.